Skip to main content

The rise of GLP-1s to improve metabolic health

Expert commentary on drugs for diabetes and weight management


Michelle Gourdine, MD, Senior Vice President and Chief Medical Officer


The Rise of GLP-1s to Improve Metabolic Health

Download the white paper (PDF)


As America confronts its obesity epidemic, plan members and providers alike have turned to glucagon-like peptide-1 receptor agonists (GLP-1s) for their significant weight loss results. Our new white paper provides a clinical backdrop for the success of this dynamic drug class. We explore the mounting demand for these drugs, how they work and what they cost, advancing health equity, and other key considerations for plan sponsors.